{
    "links": "https://www.ycombinator.com/companies/biocartesian",
    "name": "Biocartesian",
    "headline": "Converting biology into digital molecular maps",
    "batch": "S24",
    "description": "Finding new cures requires seeing what and where the abnormal molecules are in a diseased tissue, but current tools see less than 1% of those molecules. Biocartesian combines microscopy and new chemistries to see 50X more, offering unprecedented insights into disease biology and new therapies.",
    "activity_status": "Active",
    "website": "https://www.biocartesian.com",
    "founded_date": 2023.0,
    "team_size": 2.0,
    "location": "San Francisco",
    "group_partner": null,
    "group_partner_yc": null,
    "company_linkedin": null,
    "company_twitter": null,
    "tags": "industry:hard-tech; industry:b2b; industry:biotech; industry:diagnostics; industry:drug-discovery; location:san-francisco-bay-area",
    "founders": [
        {
            "name": "Ian Dardani, Founder",
            "description": "Co-founder of Biocartesian. Microscopy + molecular tools + engineering. Previously Bioscience Enterprise at Cambridge, Bioengineering PhD at UPenn.",
            "linkedin": "https://linkedin.com/in/ian-dardani"
        },
        {
            "name": "Jess Li, Founder",
            "description": "Co-founder of Biocartesian. Genetics + epigenetics, next-gen sequencing. Previously PhD at UPenn, BD at imvaria.",
            "linkedin": "https://www.linkedin.com/in/jessxli/"
        }
    ],
    "status": true,
    "generated_description": "**Biocartesian: Mapping the Future of Disease Diagnosis**\n\nFounded in 2023 and hailing from the innovative grounds of San Francisco, Biocartesian is on a mission to pioneer the way we understand biology. The company focuses on converting biological data into intricate digital molecular maps, essentially providing a more comprehensive view of disease at the molecular level. This approach springs from a significant gap in existing technologies; current tools can only observe less than 1% of abnormal molecules in diseased tissues. Biocartesian aims to change this by leveraging advanced microscopy and novel chemical methodologies to enhance visibility to an impressive 50 times more molecules.\n\nAs part of Y Combinator's Batch S24, the company's small but nimble team of two is already making waves in the hard-tech and biotech sectors. They're actively engaged in groundbreaking work that includes tissue profiling (analyzing DNA, RNA, and proteins in tissues), AI-powered data visualization and analysis, and high-throughput cellular profiling. Their technologies not only offer deeper insights into the biology of diseases but also promise to assist in the discovery of new therapies.\n\nSupported by their group partner, Nan, Biocartesian fits snugly into several tags: hard-tech, biotech, B2B, diagnostics, drug discovery, and the vibrant San Francisco Bay area ecosystem.\n\nOn the surface, the company is ambitious but grounded, focused on real-world applications that could revolutionize how we approach healthcare diagnostics and therapy development. They invite potential collaborators to connect and share ideas, emphasizing a willingness to work together in tackling these pressing challenges.\n\nYou can check out more about their work and offerings on their website [Biocartesian](https://www.biocartesian.com). \n\nIn summary, Biocartesian is not just another startup; it represents a bold step toward illuminating the complex world of biological data and disease, promising advancements that could reshape our understanding and treatment of illness in the years to come.",
    "logo": "https://bookface-images.s3.us-west-2.amazonaws.com/logos/63c7ce5f8841bdbbcf9cefd83dea394e93372474.png?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=ASIAQC4NIECAEHIR6H6F%2F20250221%2Fus-west-2%2Fs3%2Faws4_request&X-Amz-Date=20250221T191023Z&X-Amz-Expires=3600&X-Amz-Security-Token=IQoJb3JpZ2luX2VjELP%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLXdlc3QtMiJIMEYCIQDt736ZW5EfzagAz1eKRSs%2FW4TfHu28RBSFaRNkZ9h47gIhANt6WXtwkgL07bQKDKYDGFxYKx7WOO9JX0BqaYrXnKNbKu4DCNz%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEQABoMMDA2MjAxODExMDcyIgx8TqkMwTM2PLcRmr4qwgPGGtQBXv7gs7%2BXGteI1gQk%2FjkbIHwQ5hCKXJKVmVAPw3MeVLhZyp8Nf5%2FYigbwE%2BrFR7aZWKjrs7HxAE0JWit5dlINZLjZK%2BS%2FwMaCqoj%2BFDN0gw9iiAPu4Xn5c3b%2BuZe%2F5%2Flfk0EuxZAXVsZtShxXZy%2FERPQ0v%2FRZxSz5qUoaXpL1zj6VWdWVzoI7%2FPlB3bgJ2PpiF7DN%2BJeDsJPx%2FoKTo5ehP9pOeGbMNxoeegVJsCJ3zvzO3o4fcZYIf6c5iIJwM1Ot3Gg7Z3v9oLZjSRU%2FaRLL5j4n3II7DaroOCEVfPlWzTyZM7SNFZZAFSKM8vLKj1VdTr9s3How41zluf%2FOIp7sGNhG%2FjuYJoG%2FmkLFIlYP4wbGrLO69AWnenZyfi1UhAiV6N%2BlAqGnqvpOJh4vq8uNh2eRnXR%2BMVXdq9oVYkm7XFgprL5PDC4ULLyBWqA6kca4z7F4H56nkT%2FsDtT8ek2VOIRIv1Zgcz%2BeeVG7F7AHS4bdbR6eZ3ChY1iQhfPBErh4OiFQM7IqiUKw%2B1CTpvL68xcVN5gjiaDH0Jotw%2BUcW9dMSg9py8xH8qgyiWG5w3dDj9xaoA2G3NMYq6JOGKMwwIrjvQY6pAHDH54nhADhmb7YSEGxHkL3pqs%2B6aYOExStWbzLKzRb3lb2DAgGG8uU9COt8%2FqUEOtOcszTKp7yuCJwMVkfI7PDZ74h9uiRkRxjtH7%2BLlE1xrfd%2FrIq%2B%2BZr9hSFqZ9MUQ4yNHesyx2FYDbsIfCW9ntlrpmZUHCcrzpQDfufsAFcpe%2FudVT3tUqiF8WCN1Vd%2Bx%2FQ9d3i1HvBcJWV9AYAwM0W22VM%2BA%3D%3D&X-Amz-SignedHeaders=host&X-Amz-Signature=fdf00ecf78f1a0774db5dfa5bbf5616b1d6bed2174c48256486b747f601cfd32",
    "social_links": [
        "https://www.linkedin.com/company/biocartesian"
    ],
    "logo_path": "data/logos\\Biocartesian_logo.png"
}